-
1 Comment
PharmaBlock Sciences (Nanjing), Inc is currently in a long term uptrend where the price is trading 13.5% above its 200 day moving average.
From a valuation standpoint, the stock is 133.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 22.5.
PharmaBlock Sciences (Nanjing), Inc's total revenue rose by 49.9% to $297M since the same quarter in the previous year.
Its net income has increased by 20.9% to $42M since the same quarter in the previous year.
Finally, its free cash flow grew by 1440.3% to $65M since the same quarter in the previous year.
Based on the above factors, PharmaBlock Sciences (Nanjing), Inc gets an overall score of 4/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE1000035K5 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 6B |
|---|---|
| PE Ratio | 31.34 |
| Target Price | 33 |
| Dividend Yield | 1.0% |
| Beta | 0.78 |
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment based drug discovery, DNA encoded library technology, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and Full Time Equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support. In addition, it offers small molecule DP CDMO services, such as candidate screening and selection, early development, and full development; and new modality services, including target protein degrader, peptide, oligonucleotide, and ADC services. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300725.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
